Fremanezumab API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Fremanezumab API 1655501-53-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Fremanezumab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Fremanezumab
- Synonyms:
- Cas Number:
- 1655501-53-3
- DrugBank number:
- DB14041
- Unique Ingredient Identifier:
- PF8K38CG54
General Description:
Fremanezumab, identified by CAS number 1655501-53-3, is a notable compound with significant therapeutic applications. Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as , , and the oral CGRP antagonist , fremanezumab represents an important step forward in the treatment and prevention of migraine headaches.
Indications:
This drug is primarily indicated for: Fremanezumab is indicated for the preventative treatment of migraine in adults. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Fremanezumab undergoes metabolic processing primarily in: Like other monoclonal antibodies, fremanezumab is expected to undergo enzymatic proteolysis into smaller peptides and amino acids. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Fremanezumab are crucial for its therapeutic efficacy: Geometric mean ratios (GMRs) for Cmax for Japanese and Caucasian study subjects were 0.91, 1.04, and 1.14 for 225 mg, 675 mg, and 900 mg doses of fremanezumab . GMRs for AUC (0-inf) were 0.96, 1.09, and 0.98, respectively . Mean Tmax in a range of 5 to 11 days were similar across doses for both ethnicities as well . The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Fremanezumab is an important consideration for its dosing schedule: The mean half-life recorded for fremanezumab was similar across doses for Japanese and Caucasian study subjects and was estimated to be approximately 31-39 days. This determines the duration of action and helps in formulating effective dosing regimens.
Protein Binding:
Fremanezumab exhibits a strong affinity for binding with plasma proteins: Data regarding protein binding of fremanezumab are not readily available. This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Fremanezumab from the body primarily occurs through: Monoclonal antibody agents like fremanezumab are generally not eliminated via hepatic, renal, or biliary routes. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Fremanezumab is distributed throughout the body with a volume of distribution of: Fremanezumab has an apparent volume of distribution of approximately 6 liters which indicates very little distribution into tissue. This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Fremanezumab is a critical factor in determining its safe and effective dosage: The apparent clearance of fremanezumab is 0.141 L/day. It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Fremanezumab exerts its therapeutic effects through: Fremanezumab is a subcutaneous injection that targets the calcitonin gene-related peptide (CGRP) ligand, preventing its binding to the CGRP receptor. It possesses a long duration of action requiring only monthly or quarterly administration and appears well-tolerated in clinical trials. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Fremanezumab functions by: Studies dating back to 1985 have demonstrated that CGRP levels increase during acute migraine attacks in migraine-suffering patients but normalize after administration of antimigraine therapy such as . Moreover, research has shown that intravenous administration of CGRP can induce migraine-like attacks in migraine-suffering patients. For these reasons, and despite the fact that their role in migraine headaches has not been entirely elucidated, CGRP and its receptors have become desirable targets for antimigraine therapies. Fremanezumab is a humanized monoclonal antibody directed against endogenous CGRP - it interferes with the activity of CGRP, preventing its downstream effects and ultimately mitigating the development of migraine headaches. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Fremanezumab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Categories:
Fremanezumab is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Analgesics, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antimigraine Preparations, Blood Proteins, Calcitonin Gene-Related Peptide (CGRP) Antagonists, Calcitonin Gene-Related Peptide Receptor Antagonists, Globulins, Immunoglobulins, Immunoproteins, Nervous System, Proteins, Serum Globulins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Fremanezumab include:
- Molecular Weight: 148000.0
Fremanezumab is a type of Analgesics
Analgesics are a category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that are commonly used to relieve pain. They are designed to alleviate discomfort by targeting the body's pain receptors or by reducing inflammation. Analgesics are widely utilized in the medical field to manage various types of pain, ranging from mild to severe.
One of the primary classes of analgesics is nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs work by inhibiting the production of prostaglandins, substances that contribute to pain and inflammation. This class includes well-known drugs like ibuprofen and naproxen. Another class of analgesics is opioids, which are derived from opium or synthetic compounds that mimic the effects of opium. Opioids act on the central nervous system to reduce pain perception and provide potent pain relief. Examples of opioids include morphine, codeine, and oxycodone.
Analgesics are available in various forms, such as tablets, capsules, creams, and injections, allowing for different routes of administration based on the patient's needs. They are commonly used to manage pain associated with conditions like arthritis, headaches, dental procedures, and post-operative recovery.
It is important to note that analgesics should be used under medical supervision, as improper use or overuse can lead to adverse effects, including gastrointestinal complications, addiction, and respiratory depression in the case of opioids. Therefore, it is crucial for healthcare professionals to assess each patient's individual needs and prescribe the appropriate analgesic and dosage.
In summary, analgesics are a vital category of pharmaceutical APIs used to alleviate pain by targeting pain receptors or reducing inflammation. With various classes and forms available, they provide valuable options for pain management when used responsibly and under medical guidance.
